Human Anti-HIV-1 gp120 Recombinant Antibody (clone PG16) (CAT#: PABX-097)

Figure 1 Flow cytometry dot plots showing the binding capacity of F6 to HIV-1BJMSM2316 and HIV-1BJMSM2316_D368R GP160 on the surface of transfected 293 T cells.

Ju, B., Li, D., Ren, L., Hou, J., Hao, Y., Liang, H., ... & Shao, Y. (2018). Identification of a novel broadly HIV-1-neutralizing antibody from a CRF01_AE-infected Chinese donor. Emerging microbes & infections, 7(1), 1-12.

Figure 2 ELISA binding of F6 to TriMut and TriMut/368/370/474. c Competition neutralizing of F6 against HIV-1BJMSM2316 with TriMut and TriMut/368/370/474.

Ju, B., Li, D., Ren, L., Hou, J., Hao, Y., Liang, H., ... & Shao, Y. (2018). Identification of a novel broadly HIV-1-neutralizing antibody from a CRF01_AE-infected Chinese donor. Emerging microbes & infections, 7(1), 1-12.

Figure 3 Localization of GPI-anchored CDR H3 in transduced TZM-bl cells.

Shown are data for confocal analysis of mock- or GPI-CDR H3(PG16 and AVF)-transduced TZM-bl cells. Cells were stained with Alexa 555-conjugated cholera toxin B subunit (CtxB), and cells were stained with a mouse anti-His tag antibody followed by Alexa 488-conjugated goat anti-mouse IgG antibody.

Liu, L., Wen, M., Wang, W., Wang, S., Yang, L., Liu, Y., ... & Zhou, P. (2011). Potent and broad anti-HIV-1 activity exhibited by a glycosyl-phosphatidylinositol-anchored peptide derived from the CDR H3 of broadly neutralizing antibody PG16. Journal of virology, 85(17), 8467-8476.

Figure 4 Effect of GPI-CDR H3(PG16) on anti-HIV-1 activity of transduced human CD4
T cells.

(A) GPI-CDR H3(PG16) confers resistance to HIV-1 Bru-3 in human CD4
T cells. (B) GPI-CDR H3(PG16) confers resistance to HIV-1 Bru-Yu2 in human CD4
T cells.

Liu, L., Wen, M., Wang, W., Wang, S., Yang, L., Liu, Y., ... & Zhou, P. (2011). Potent and broad anti-HIV-1 activity exhibited by a glycosyl-phosphatidylinositol-anchored peptide derived from the CDR H3 of broadly neutralizing antibody PG16. Journal of virology, 85(17), 8467-8476.